Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database by Tingting Jiang, Yanping Li, Ni Zhang, Lanlan Gan, Hui Su, Guiyuan Xiang, Yuanlin Wu, Yao Liu

Get full text

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis by Guiyuan Xiang, Yueyue Huang, Ni Zhang, Xinyu Du, Yuanlin Wu, Lanlan Gan, Yanping Li, Tingting Jiang, Yao Liu

Get full text